10
Nov
Big Changes for Hormone Replacement Therapy Announced by FDA - Lachman Blog

Big Changes for Hormone Replacement Therapy Announced by FDA

In an announcement today, the FDA has explained its decision to revise the labeling of hormone replacement therapy (HRT) products based on reevaluation of older studies in light of new data. The FDA recognizes a difference between the risks associated with oral HRT products vs. vaginally applied HRT products and the labeling changes reflect this […]

Read More
06
Nov
Traffic jam on the polluted streets of New Delhi, India.

FDA Announces Next Batch of Commissioner’s National Priority Vouchers (CNPVs)

With the addition of the six new vouchers awarded today, the total number of CNPVs awarded is fifteen.  It’s interesting to note that Dr. George Tidmarsh, the short-time CDER Director, was reported to have been critical of the CNPV program, worried that the compressed one to two month review and approval times would compromise safety and […]

Read More
30
Oct
FY 2026 Applications - Lachman Blog

If You Must Remit, You Can’t Submit = Big Problem for Industry

As we near the end of October 2025, the first month of new FY 2026, and as FDA appropriations languish in our dysfunctional Congress, the number of fee-paying submissions submitted to FDA so far in the new Fiscal Year 2026 = 0. That’s right nada, nil, zero, zilch, none. You can count the number on […]

Read More
20
Oct
Priority Review Voucher - Lachman Blog

Commissioners National Priority Vouchers Awarded to Nine Sponsors

The Commissioner’s National Priority Voucher (CNPV) program is designed to shorten the review times of complete submitted New Drug Applications (NDAs) and Biologics License Applications (BLAs) from a standard ten months to two months.  We have written previous blogs on this topic as can be seen here, here, and here and have expressed some concerns […]

Read More
13
Oct
Should FDA Make Drug Pricing Part of the Review and Approval Process - Lachman Blog

Should FDA Make Drug Pricing Part of the Review and Approval Process? I Don’t Think So

Secretary Kennedy has basically accused much of the FDA and other parts of the HHS organization of being corrupt. One of his stated goals was to root out corruption. However, he never explicitly defined what the corruption was or identified any individual accused of it. Instead, he spoke of the revolving door where FDA employees […]

Read More
22
Sep
Changes Ahead Wet floor sign

Revised Draft Guidance on Safety Labeling Changes – Implementation of Section 505(o)(4) of the FD&C Act

FDA announced a new revised draft guidance which “is being updated and reissued in draft to, among other things, include the addition of information related to Congress’ 2018 changes to the definition of adverse drug experience regarding reduced effectiveness and make other changes to reflect current Agency processes and procedures regarding safety labeling changes. This […]

Read More
18
Sep
Money finance USA dollar

Fee Rate Announced for Using a Priority Review Voucher in Fiscal Year 2026

Priority review vouchers are awarded to the sponsors of applications for tropical disease, rare pediatric disease, or material threat medical countermeasure (MCM) products that gain approval.  The new fee for use of a priority review voucher is the same for each type of voucher as identified in the table below: The pre-publication Federal Register Notice […]

Read More
15
Sep
Senior man, with back pain, touches his back, illustrating sciatica and sedentary lifestyle. Emphasizing spine health and the significance of healthcare and insurance in this stock image.

The FDA Issues Draft Guidance for Non-Opioid Chronic Pain Products – It Has Been an Arduous Quest for Industry!

The opioid crisis continues, and the battle of addiction remains ongoing as well. The FDA has approved one new non-opioid pain reliever (Journavx (suzetrigine tablets)) for moderate to severe acute pain in adults. The application holder UC Health claims (here) “[T]his new oral painkiller — the first approved by the FDA in more than 20 […]

Read More
1 … 5 6 7 … 35